Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Paper
  • Published:

Neoplastic progression in melanoma and colon cancer is associated with increased expression and activity of the interferon-inducible protein kinase, PKR

Abstract

The interferon-inducible, double-stranded RNA (dsRNA)-activated protein kinase, PKR, plays key roles in regulation of cell growth and differentiation, and has been postulated as a tumor suppressor. Downstream effectors of PKR include the translation initiation factor, eIF2α, and the transcription factor, NF-κB. We found elevated levels of PKR protein, dsRNA-dependent PKR autophosphorylation activity, and phosphorylated eIF2α in melanoma cells compared to nontransformed melanocytes in culture. Treatment with interferon-α2b further induced PKR expression and activity. Immunohistochemical analysis of primary melanomas demonstrated minimal PKR immunoreactivity, but melanoma lymph node metastases expressed a high level of PKR protein. Furthermore, analysis of colon cancer specimens revealed that transformation from normal mucosa to adenomas and carcinomas was coincident with an increase in PKR expression. These data do not support the concept of PKR as a classic tumor suppressor but instead suggest that PKR upregulation occurs at defined steps in cancer progression, probably as a cellular response to neoplasia.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  • Abraham N, Stojdl DF, Duncan PI, Methot N, Ishii T, Dube M, Vanderhyden BC, Atkins HL, Gray DA, McBurney MW, Koromilas AE, Brown EG, Sonenberg N, Bell JC . 1999 J. Biol. Chem. 274: 5953–5962

  • Barber GN . 2001 Cell Death Differ. 8: 113–126

  • Barber GN, Jagus R, Meurs EF, Hovanessian AG, Katze MG . 1995 J. Biol. Chem. 270: 17423–17428

  • Bonnet MC, Weil R, Dam E, Hovanessian AG, Meurs EF . 2000 Mol. Cell. Biol. 20: 4532–4542

  • Carey TE, Takahashi T, Resnick LA, Oettgen HF, Old LJ . 1976 Proc. Natl. Acad. Sci. USA 73: 3278–3282

  • Clemens MJ, Bommer UA . 1999 Int. J. Biochem. Cell Biol. 31: 1–23

  • Delhem N, Sabile A, Gajardo R, Podevin P, Abadie A, Blaton MA, Kremsdorf D, Beretta L, Brechot C . 2001 Oncogene 20: 5836–5845

  • Donze O, Jagus R, Koromilas AE, Hershey JW, Sonenberg N . 1995 EMBO J. 14: 3828–3834

  • Gil J, Alcami J, Esteban M . 2000 Oncogene 19: 1369–1378

  • Gil J, Esteban M . 2000 Apoptosis 5: 107–114

  • Gil J, Rullas J, Garcia MA, Alcami J, Esteban M . 2001 Oncogene 20: 385–394

  • Green SR, Mathews MB . 1992 Genes Dev. 6: 2478–2490

  • Haines III GK, Panos RJ, Bak PM, Brown T, Zielinski M, Leyland J, Radosevich JA . 1998 Tumour Biol. 19: 52–59

  • Haines GK, Becker S, Ghadge G, Kies M, Pelzer H, Radosevich JA . 1993a Arch. Otolaryngol. Head Neck Surg. 119: 1142–1147

  • Haines GK, Cajulis R, Hayden R, Duda R, Talamonti M, Radosevich JA . 1996 Tumour Biol. 17: 5–12

  • Haines GK, Ghadge G, Thimmappaya B, Radosevich JA . 1992 Virchows Arch. B. Cell. Pathol. Incl. Mol. Pathol. 62: 151–158

  • Haines GK, Ghadge GD, Becker S, Kies M, Pelzer H, Thimmappaya B, Radosevich JA . 1993b Virchows Arch. B. Cell. Pathol. Incl. Mol. Pathol. 63: 289–295

  • Ishii T, Kwon H, Hiscott J, Mosialos G, Koromilas AE . 2001 Oncogene 20: 1900–1912

  • Jagus R, Joshi B, Barber GN . 1999 Int. J. Biochem. Cell. Biol. 31: 123–138

  • Jaramillo M, Abraham N, Bell J . 1995 Cancer Invest. 13: 327–338

  • Kim S, Coit D . 1998 Cutaneous Oncology: Pathophysiology, Diagnosis, and Treatment Miller S and Maloney M (eds) Cambridge, MA: Blackwell Science, Inc pp 303–315

    Google Scholar 

  • Kim SH, Forman AP, Mathews MB, Gunnery S . 2000 Oncogene 19: 3086–3094

  • Kinzler KW, Vogelstein B . 1996 Cell 87: 159–170

  • Kirkwood J, Strawderman M, Ernstoff M, Smith T, Borden E, Blum R . 1996 J. Clin. Oncol. 14: 7–17

  • Koromilas AE, Roy S, Barber GN, Katze MG, Sonenberg N . 1992 Science 257: 1685–1689

  • Laemmli UK . 1970 Nature 227: 680–685

  • Mathews MB, Pe'ery T . 2001 Trends Biochem. Sci. 26: 585–587

  • Meurs EF, Galabru J, Barber GN, Katze MG, Hovanessian AG . 1993 Proc. Natl. Acad. Sci. USA 90: 232–236

  • Offermann MK, Zimring J, Mellits KH, Hagan MK, Shaw R, Medford RM, Mathews MB, Goodbourn S, Jagus R . 1995 Eur. J. Biochem. 232: 28–36

  • Oldfield S, Jones BL, Tanton D, Proud CG . 1994 Eur. J. Biochem. 221: 399–410

  • Pataer A, Vorburger SA, Barber GN, Chada S, Mhashilkar AM, Zou-Yang H, Stewart AL, Balachandran S, Roth JA, Hunt KK, Swisher SG . 2002 Cancer Res. 62: 2239–2243

  • Pehamberger H, Soyer HP, Steiner A, Kofler R, Binder M, Mischer P, Pachinger W, Aubock J, Fritsch P, Kerl H, Wolff K . 1998 J. Clin. Oncol. 16: 1425–1429

  • Proud CG . 1995 Trends Biochem. Sci. 20: 241–246

  • Raveh T, Hovanessian AG, Meurs EF, Sonenberg N, Kimchi A . 1996 J. Biol. Chem. 271: 25479–25484

  • Romano PR, Garcia-Barrio MT, Zhang X, Wang Q, Taylor DR, Zhang F, Herring C, Mathews MB, Qin J, Hinnebusch AG . 1998 Mol. Cell. Biol. 18: 2282–2297

  • Samuel CE . 2001 Clin. Microbiol. Rev. 14: 778–809 table of contents

  • Savinova O, Joshi B, Jagus R . 1999 Int. J. Biochem. Cell. Biol. 31: 175–189

  • Shang Y, Baumrucker CR, Green MH . 1998 J. Biol. Chem. 273: 30608–30613

  • Shimada A, Shiota G, Miyata H, Kamahora T, Kawasaki H, Shiraki K, Hino S, Terada T . 1998 Cancer Res. 58: 4434–4438

  • Sieber OM, Tomlinson IP, Lamlum H . 2000 Mol. Med. Today 6: 462–469

  • Singh C, Haines GK, Talamonti MS, Radosevich JA . 1995 Tumour Biol. 16: 281–289

  • Sudhakar A, Ramachandran A, Ghosh S, Hasnain SE, Kaufman RJ, Ramaiah KV . 2000 Biochemistry 39: 12929–12938

  • Terada T, Maeta H, Endo K, Ohta T . 2000a Hum. Pathol. 31: 817–821

  • Terada T, Ueyama J, Ukita Y, Ohta T . 2000b Liver 20: 450–457

  • Williams BR . 1999 Oncogene 18: 6112–6120

  • Williams BR . 2001 Sci. STKE 2001: RE2

  • Yang YL, Reis LF, Pavlovic J, Aguzzi A, Schafer R, Kumar A, Williams BR, Aguet M, Weissmann C . 1995 EMBO J. 14: 6095–6106

  • Zamanian-Daryoush M, Der SD, Williams BR . 1999 Oncogene 18: 315–326

  • Zamanian-Daryoush M, Mogensen TH, DiDonato JA, Williams BR . 2000 Mol. Cell. Biol. 20: 1278–1290

  • Zhou Y, Gobl A, Wang S, Jacobsen MB, Janson ET, Haines III GK, Radosevich JA, Oberg K . 1998 Eur. J. Cancer 34: 2046–2052

Download references

Acknowledgements

We wish to thank Gene Marquet for valuable technical assistance with the immunohistochemistry. This work was supported by grant AI34552 to MBM from the National Institute of Health.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Steve H Kim.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kim, S., Gunnery, S., Choe, J. et al. Neoplastic progression in melanoma and colon cancer is associated with increased expression and activity of the interferon-inducible protein kinase, PKR. Oncogene 21, 8741–8748 (2002). https://doi.org/10.1038/sj.onc.1205987

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205987

Keywords

This article is cited by

Search

Quick links